Radium-223 chloride - Bayer HealthCare

Drug Profile

Radium-223 chloride - Bayer HealthCare

Alternative Names: AC1O4D1M; Alpharadin; ATI-BC-1; BAY88-8223; Radium Ra 233 dichloride; Radium-223; Radium-223 dichloride; Xofigo

Latest Information Update: 16 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Algeta
  • Developer Algeta; Bayer HealthCare; Janssen; Medica Scientia Innovation Research; Thomas Jefferson University; University of Texas M. D. Anderson Cancer Center; University of Utah
  • Class Antineoplastics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone metastases
  • Phase II Prostate cancer
  • Phase I/II Multiple myeloma
  • No development reported Osteosarcoma
  • Discontinued Cancer pain

Most Recent Events

  • 13 Jul 2018 The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) recommends restricting use of radium-223 chloride (Xofigo) for Prostate cancer
  • 12 Feb 2018 Phase-II clinical trials in Prostate cancer (Second-line therapy or greater) in USA (IV) (NCT03304418)
  • 30 Nov 2017 The Independent Data Monitoring Committee recommends early unblinding of the phase III ERA223 trial in Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top